KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Current Deferred Revenue: 2020-2024

Historic Current Deferred Revenue for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $61.8 million.

  • Recursion Pharmaceuticals' Current Deferred Revenue fell 4.47% to $47.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.4 million, marking a year-over-year decrease of 4.47%. This contributed to the annual value of $61.8 million for FY2024, which is 69.57% up from last year.
  • As of FY2024, Recursion Pharmaceuticals' Current Deferred Revenue stood at $61.8 million, which was up 69.57% from $36.4 million recorded in FY2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Current Deferred Revenue peaked at $61.8 million during FY2024, and registered a low of $10.0 million during FY2020.
  • Moreover, its 3-year median value for Current Deferred Revenue was $56.7 million (2022), whereas its average is $51.6 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Current Deferred Revenue surged by 467.26% in 2022 and then plummeted by 35.79% in 2023.
  • Over the past 5 years, Recursion Pharmaceuticals' Current Deferred Revenue (Yearly) stood at $10.0 million in 2020, then remained steady at $10.0 million in 2021, then soared by 467.26% to $56.7 million in 2022, then tumbled by 35.79% to $36.4 million in 2023, then soared by 69.57% to $61.8 million in 2024.